Policy Conference on The Potential for QT Prolongation and Proarrhythmia by Non-antiarrhythmic Drugs: Clinical and Regulatory Implications, Sophia Antipolis, France, 24-25 June 1999

European Heart Journal

Volumn 21, Issue 15, 2000, Pages 1216-1231

  Haverkamp, W ^a   Breithardt, G ^a   Camm, A J ^a   Janse, M J ^a   Rosen, M R ^a   Antzelevitch, C ^a   Escande, D ^a   Franz, M ^a   Malik, M ^a   Moss, A ^a   Shah, R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; ANTIARRHYTHMIC AGENT; ANTIINFLAMMATORY AGENT; NEUROLEPTIC AGENT; VASODILATOR AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; HEART ARRHYTHMIA; HEART REPOLARIZATION; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES; ACTION POTENTIAL; ANIMAL; CARDIOLOGY; CHEMICALLY INDUCED DISORDER; CONSENSUS DEVELOPMENT; DRUG APPROVAL; DRUG EFFECT; ELECTROCARDIOGRAPHY; EUROPE; HEART MUSCLE; LEGAL ASPECT; LONG QT SYNDROME; MANAGEMENT; MEDICAL SOCIETY; METABOLISM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIPSYCHOTIC AGENTS; CARDIOLOGY; DRUG APPROVAL; ELECTROCARDIOGRAPHY; EUROPE; HUMANS; LONG QT SYNDROME; MYOCARDIUM; POLICY MAKING; PRACTICE GUIDELINES; SOCIETIES, MEDICAL; VASODILATOR AGENTS;

EID: 0034244378     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2249     Document Type: Conference Paper

References (81)

1. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation. 30:1964;17-26.
2. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 111:1986;1088-1093.
3. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. 2:1983;806-817.
4. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Swiryn S, Rosen KM. Torsades de pointes due to quinidine: observations in 31 patients. Am Heart J. 107:1984;425-430.
5. Haverkamp W, Martinez RA, Hief C. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol. 30:1997;487-495.
6. Lehmann MH, Hardy S, Archibald D, Quart B, McNeil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 94:1996;2535-2541.
7. Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol. 80:1997;82G-9G.
8. Torp-Pederson C, Moller M, Bloch-Thomsen PE. for The Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 341:1999;879-911.
9. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, Van der Lugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 94:1996;1613-1621.
10. Zipes DP. Unwitting exposure to risk. Cardiol Rev. 1993;1-3.
11. Rosen MR. Of oocytes and runny noses. Circulation. 94:1996;607-609.
12. Priori SG. Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol. 9:1998;1114-1116.
13. Ks, absent from undiseased human ventricular myocardium? Cardiovasc Res. 40:1998;433-435.
14. Varro A, Balati B, Iost N. The role of the delayed rectifier component Iks in dog ventricular muscle and Purkinje fiber repolarization. J Physiol. 523:2000;67-81.
15. Liu DW, Antzelevitch C. Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A weaker IKs contributes to the longer action potential of M cells. Circ Res. 76:1995;351-365.
16. Ks. Am J Physiol. 271:1996;H2477-89.
17. Ye L, Feng J, Li GR, Nattel S. Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods. Am J Physiol. 272:1996;H1292-H1301.
18. Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 42:1999;270-283.
19. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol. 23:1994;259-277.
20. Viswanathan PC, Rudy Y. Pause induced early afterdepolarizations in the long QT syndrome: a simulation study. Cardiovasc Res. 42:1999;530-542.
21. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Lindhardt G. Proarrhythmic effects of class III agent almokalant: importance of infusion rate, QT dispersion and early after depolarizations. Cardiovasc Res. 27:1993;2186-2193.
22. Burashnikov A, Antzelevitch C. Acceleration-induced action potential prolongation and early afterdepolarizations. J Cardiovasc Electrophysiol. 9:1998;934-948.
23. El-Sherif N, Caref FB, Yin H, Restivo M. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. Circ Res. 79:1996;474-492.
24. Surawicz B. Electrophysiological substrate for Torsade de pointes: Dispersion of refractoriness or early afterdepolarizations. J Am Coll Cardiol. 14:1989;172-184.
25. Verduyn SC, Vos MA, Van der Zande J, Van der Hulst FF, Wellens HJJ. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium. Cardiovasc Res. 34:1997;453-463.
26. Antzelevitch C, Shimizu W, Yan GX. The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol. 10:1999;1124-1152.
27. Yan G-X, Shimizu W, Antzelevitch C. Characteristics and distribution of M-cells in arterially perfused canine left ventricular wedge preparations. Circulation. 98:1998;1921-1927.
28. Janse MJ, Capucci A, Coronel R, Fabius MAW. Variability of recovery of excitability in the normal canine and the ischaemic porcine heart. Eur Heart J. 6:1985;41-50.
29. Anyukhovsky EP, Sosunov EA, Rosen MR. Regional differences in electrophysiological properties of epicardium, midmyocardium, and endocardium. In vitro and in vivo correlations. Circulation. 94:1996;1981-1988.
30. Merot J, Charpentier F, Poirier JM, Coutris J, Weissenburger J. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: Interactions with acute sotalol. Cardiovasc Res. 44:1999;303-314.
31. +channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol. 273:1997;H2534-8.
32. Vitola J, Vukanovic J, Roden DM. Cisapride-induced Torsade de Pointes. J Cardiovasc Electrophysiol. 9:1998;1109-1113.
33. Roden DM, Spooner PM. Inherited long QT syndromes. A paradigm for understanding arrhythmias. J Cardiovasc Electrophysiol. 10:1999;1664-1683.
34. Houltz B, Darpö B, Edvardsson N, Blomstrom P, Brachmann J, Crijns HJ, Jensen SM, Svernhage E, Vallin H, Swedberg K. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study. PACE. 21:1998;1044-1057.
35. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 97:1999;175-187.
36. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: Clinical impact. Circulation. 99:1999;529-533.
37. Roden DM. Taking the 'idio' out of 'idiosyncratic': Predicting torsades de pointes. PACE. 21:1998;1029-1034.
38. Soffer J, Dreifus LS, Michelson EL. Polymorphous ventricular tachycardia associated with normal and long Q-T intervals. Am J Cardiol. 49:1982;2021-2029.
39. Breithardt G, Seipel L, Haerten K. Paradoxic response to disopyramide and quinidine. Z Kardiol. 69:1980;556-561.
40. Wald RW, Waxman MB, Colman JM. Torsade de pointes ventricular tachycardia. A complication of disopyramide shared with quinidine. J Electrocardiol. 14:1981;301-307.
41. Hohnloser SH, van der Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol. 26:1995;852-858.
42. Dascal N. The use of Xenopus oocytes for the study of ion channels. Crit Rev Biochem. 22:1987;341-356.
43. Stühmer W, Parekh AB. Electrophysiological recordings from Xenopus oocytes. Sackmann B, Neher E. Single-Channel Recordings. 1995;341-356 Plenum Press, New York.
44. Fishman GI, McDonald TV. Gene transfer of membrane channel proteins. Zipes DP, Jalife J. Cardiac Electrophysiology. From Cell to Bedside. 2000;58-66 Saunders Company, Philadelphia.
45. Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther. 262:1992;99-108.
46. January CT, Riddle JM. Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res. 64:1989;977-990.
47. Busch AE, Malloy K, Groh WJ, Varnum MD, Adelman JP, Maylie J. The novel class III antiarrhythmics NE-10064 and NE-10133 inhibit IsK channels expressed in Xenopus oocytes and IKs in guinea pig cardiac myocytes. Biochem Biophys Res Commun. 202:1994;265-270.
48. Coronel R, Opthof T, Taggart P, Tygat J, Veldkamp M. Differential electrophysiology of repolarization from clone to clinic. Cardiovasc Res. 33:1997;503-517.
49. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation. 94:1996;1471-1474.
50. Pinney SP, Koller BS, Franz MR, Woosley RL. Terfenadine increases the QT interval in isolated guinea pig heart. J Cardiovasc Pharmacol. 25:1995;30-34.
51. Eckardt L, Haverkamp W, Mertens H. Drug related torsade de pointes in the isolated rabbit heart: Comparison of clofilium, d,l-sotalol and erythromycin. J Cardiovasc Pharmacol. 32:1998;425-434.
52. Zabel M, Hohnloser SH, Behrens S, Li Y-G, Woosley RL, Franz MR. Electrophysiologic features of torsade de pointes: Insights from a new rabbit heart model. J Cardiovasc Electrophysiol. 8:1997;1148-1158.
53. Johna R, Mertens H, Haverkamp W. Clofilium in the isolated perfused rabbit heart: A new model to study proarrhythmia by class III antiarrhythmic drugs. Basic Res Cardiol. 93:1998;127-135.
54. Sosunov EA, Gainullin RZ, Danilo PJ, Anyukhovsky EP, Kirchengast M, Rosen MR. Electrophysiological effects of LU111995 on canine hearts: In vivo and in vitro studies. J Pharmacol Exp Ther. 290:1999;146-152.
55. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential? J Pharmacol Exp Ther. 282:1997;220-227.
56. Detweiler DK. Electrocardiography in toxicological studies. Sipes IG, McQueen CA, Gandolfi AJ. Comprehensive Toxicology. 1977;95-114 Pergamon Press, New York.
57. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions. J Cardiovasc Pharmacol. 16:1990;276-285.
58. Chezalviel-Guilbert F, Davy JM, Poirier JM, Weissenburger J. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrythmic effects in a canine model of torsade de pointes. J Am Coll Cardiol. 26:1995;787-792.
59. Weissenburger J, Davy JM, Chezalviel F. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. J Pharmacol Exp Ther. 259:1991;871-883.
60. Vos MA, Verduyn SC, Gorgels AP, Lipcsei GC, Wellens HJJ. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation. 91:1995;864-872.
61. Vos MA, de Groot SHM, Verduyn SC. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation. 98:1998;1125-1135.
62. Committee for Proprietary Medicinal Products (CPMP), Points to Consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products, 1997.
63. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol. 72:1993;22B-3B.
64. Ahnve S. Correction of the QT interval for heart rate: Review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J. 109:1985;568-574.
65. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol. 70:1992;797-801.
66. Hnatkova K, Malik M. 'Optimum' formulae for heart rate correction of the QT interval. PACE. 22:1999;1683-1687.
67. Honig, PK, Wortham, DC, Zamani, K, Conner, DP, Mullin, JC, Cantilena, LR, Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA, 1993, 269, 1513, 18.
68. Bauman JL, Sanoski CA, Chan LN. Pharmacokinetic and pharmacodynamic drug interactions with antiarrhythmic agents. Cardiol Rev. 5:1997;292-304.
69. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S, Ruskin J, Moye L. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability. Am Heart J. 131:1996;472-480.
70. Cavuto NJ, Woosley RL, Sale M, Bates DW, Leape LL. Pharmacies and prevention of potentially fatal drug interactions. JAMA. 275:1996;1086-1087.
71. Thompson D, Oster G. Use of terfenadine and contraindicated drugs. JAMA, 275:1996;1339-1341.
72. Anonymous, 'Janssen Propulsid Prescribing For Inpatients Questioned in Three Studies'. F-D-C Report 'The Pink Sheet' 1998, 60, 26.
73. Kr. Circulation. 93:1996;407-411.
74. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 81:1990;686-690.
75. Makkar RR, Fromm BS, Steinman RT, Leissner MD, Lehmann MH. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA. 270:1993;2547-2590.
76. Liu X-K, Katchman A, Drici M-D. Gender differences in the cycle-length dependent QT and potassium currents in rabbits. J Pharm Exp Ther. 285:1998;672-679.
77. Vermeulen JT, McGuire MA, Opthof T. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc Res. 28:1994;1547-1554.
78. Roy M, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation. 94:1996;817-823.
79. Hirao H, Shimizu W, Kurita T. Frequency-dependent electrophysiological properties of ventricular repolarization in patients with congenital long QT syndrome. J Am Coll Cardiol. 28:1996;1269-1277.
80. Sun Z-H, Swan H, Viitasalo M, Toivonen L. Effects of epinephrine and phenylephrine of QT interval dispersion in congenital long QT syndrome. J Am Coll Cardiol. 31:1998;1400-1405.
81. Shimizu W, Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome. Effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation. 98:1998;2314-2322.